Loading…
Jupiter Life Line Hospitals (JLHL)₹292.20−0.43%Hospital
In the Sep 2026 quarter (consolidated), Jupiter Life Line Hospitals reported sales of ₹455 Cr, up 15.8% from Sep 2025, and net profit of ₹56.17 Cr, down 1.7% year on year. For the year to Mar 2026, sales were ₹1,496 Cr and net profit ₹195 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 272 | 290 | 288 | 334 | 332 | 336 | 352 | 393 | 364 | 387 | 410 | 455 |
| Expenses | 211 | 228 | 223 | 257 | 256 | 257 | 275 | 301 | 282 | 299 | 332 | 351 |
| Operating Profit | 61.73 | 62.72 | 64.72 | 77.67 | 75.70 | 79.66 | 77.75 | 91.61 | 82.72 | 88.58 | 78.71 | 107 |
| OPM % | 23.0% | 22.0% | 23.0% | 23.0% | 23.0% | 24.0% | 22.0% | 23.0% | 23.0% | 23.0% | 19.0% | 23.0% |
| Other Income | 8.02 | 10.02 | 7.02 | 7.02 | 7.02 | 7.02 | 13.03 | 11.02 | 3.01 | 11.03 | 11.03 | 11.03 |
| Interest | 1.01 | 1.01 | 1.01 | 1.01 | 3.01 | 6.02 | 8.03 | 8.03 | 8.02 | 9.03 | 13.04 | 14.06 |
| Depreciation | 11.02 | 10.01 | 11.02 | 14.01 | 14.01 | 18.03 | 21.04 | 21.02 | 22.05 | 23.03 | 26.04 | 28.05 |
| Profit before tax | 58.08 | 62.04 | 60.10 | 70.11 | 67.08 | 63.03 | 62.07 | 74.05 | 57.08 | 68.07 | 51.06 | 75.06 |
| Tax % | 24.9% | 26.9% | 25.9% | 26.0% | 21.9% | 27.9% | 29.0% | 23.0% | 24.9% | 26.0% | 25.9% | 24.9% |
| Exceptional items | 0.00 | 2.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −5.01 | 1.01 | 0.00 | 0.00 |
| Net Profit | 44.13 | 45.13 | 45.12 | 52.15 | 52.16 | 45.09 | 44.11 | 57.15 | 42.11 | 50.14 | 38.09 | 56.17 |
| EPS (Rs) | 1.32 | 1.36 | 1.35 | 1.57 | 1.58 | 1.37 | 1.33 | 1.74 | 1.29 | 1.52 | 1.13 | 1.70 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 461 | 485 | 731 | 891 | 1,069 | 1,299 | 1,496 | 1,615 |
| Expenses | 379 | 420 | 581 | 692 | 832 | 1,000 | 1,157 | 1,265 |
| Operating Profit | 83.63 | 66.70 | 152 | 200 | 241 | 302 | 341 | 357 |
| OPM % | 18.0% | 14.0% | 21.0% | 23.0% | 23.0% | 23.0% | 23.0% | 22.1% |
| Other Income | 0.00 | 4.01 | 4.01 | 8.02 | 22.04 | 25.06 | 37.12 | 36.10 |
| Interest | 26.09 | 39.14 | 44.14 | 42.16 | 26.09 | 11.05 | 33.09 | 44.15 |
| Depreciation | 26.05 | 31.04 | 36.05 | 39.03 | 42.05 | 57.11 | 88.10 | 99.17 |
| Profit before tax | 33.06 | 2.01 | 77.08 | 129 | 195 | 261 | 260 | 251 |
| Tax % | 10.0% | 247.9% | 33.9% | 42.9% | 9.9% | 25.9% | 25.0% | — |
| Exceptional items | −1.01 | 0.00 | 0.00 | −1.01 | 0.00 | 3.01 | 5.01 | −4.00 |
| Net Profit | 30.07 | −2.01 | 51.11 | 73.16 | 178 | 194 | 195 | 187 |
| EPS (Rs) | 1.16 | −0.08 | 2.00 | 2.57 | 5.38 | 5.88 | 5.91 | 5.64 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 4.0% | 3.0% | 3.0% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 51.11 | 51.14 | 51.15 | 57.15 | 66.11 | 66.08 | 66.15 |
| Reserves | 186 | 188 | 244 | 310 | 1,104 | 1,292 | 1,481 |
| Borrowings | 273 | 427 | 496 | 470 | 0.00 | 394 | 585 |
| Other Liabilities | 94.44 | 125 | 121 | 152 | 113 | 169 | 236 |
| Total Liabilities | 604 | 791 | 912 | 989 | 1,283 | 1,920 | 2,368 |
| Fixed Assets | 437 | 633 | 687 | 723 | 720 | 981 | 1,390 |
| CWIP | 9.99 | 26.02 | 26.99 | 29.02 | 74.05 | 185 | 129 |
| Investments | 1.99 | 6.99 | 2.99 | 1.99 | 16.99 | 507 | 485 |
| Other Assets | 156 | 126 | 195 | 235 | 472 | 247 | 363 |
| Inventories | 13.97 | 12.98 | 14.97 | 18.98 | 20.96 | 25.93 | 37.93 |
| Trade receivables | 44.87 | 21.95 | 27.94 | 45.86 | 56.86 | 42.91 | 75.74 |
| Cash & equivalents | 7.02 | 19.04 | 103 | 134 | 302 | 95.16 | 58.09 |
| Total Assets | 604 | 791 | 912 | 989 | 1,283 | 1,920 | 2,368 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 74.07 | 123 | 137 | 176 | 115 | 267 | 268 |
| Cash from investing activity | −42.92 | −294 | −83.78 | −93.79 | −246 | −496 | −441 |
| Cash from financing activity | −32.05 | 184 | 32.05 | −51.09 | 128 | 297 | 136 |
| Net cash flow | −0.99 | 11.97 | 84.80 | 30.92 | −2.99 | 65.81 | −37.92 |
| Capex | 28.98 | 242 | 91.92 | 76.94 | 84.99 | 328 | 502 |
| Free cash flow | 46.06 | −118 | 46.02 | 100 | 29.03 | −60.03 | −234 |
| CFO / OP % | 106.1% | 198.1% | 95.1% | 97.1% | 68.1% | 109.1% | 97.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 35 | 16 | 14 | 19 | 19 | 12 | 18 |
| Inventory days | 64 | 48 | 39 | 44 | 41 | 38 | 49 |
| Days payable | 267 | 216 | 156 | 163 | 119 | 98 | 120 |
| Cash conversion cycle | −169 | −152 | −104 | −101 | −59 | −49 | −54 |
| Working capital days | 18 | −6 | −23 | −23 | −4 | −18 | −20 |
| ROCE % | — | 7.0% | 17.0% | 21.0% | 22.0% | 18.0% | 15.0% |
For the Sep 2026 quarter, Jupiter Life Line Hospitals reported sales of ₹455 Cr, up 15.8% year on year and net profit of ₹56.17 Cr, down 1.7% year on year. The operating margin was 23.0%.
Jupiter Life Line Hospitals' sales for the year to Mar 2026 were ₹1,496 Cr; over the last twelve months they were ₹1,615 Cr.
Net profit for the year to Mar 2026 was ₹195 Cr, and ₹187 Cr over the last twelve months. Earnings per share over the same trailing period were ₹5.64.
Jupiter Life Line Hospitals reported borrowings of ₹585 Cr at Mar 2026, against cash and equivalents of ₹58.09 Cr.
Cash from operations was ₹268 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹234 Cr.